Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,916 total articles

BRIUMVI Momentum + Selective Buybacks: A Tactical Long on TGTX

BRIUMVI Momentum + Selective Buybacks: A Tactical Long on TGTX

TG Therapeutics' BRIUMVI continues to drive outsized top-line growth, management is leaning into commercial expansion and awareness campaigns, and the stock trades at a reasonable P/E for a growth-to-profit story. We recommend a tactical long with a $33.20 entry, $46.48 target and $29.00 stop, horizon ~180 trading days.

Meta: Time to Bear Hunt in the Value Valley

Meta: Time to Bear Hunt in the Value Valley

Meta ($META) looks vulnerable despite recent strength. Fundamentals are solid but priced for perfection: P/E ~22.8, P/S ~6.8 and stretched technicals leave room for a re-test of the low $400s if ad growth disappoints or Reality Labs costs re-emerge. This is a mid-term (45 trading days) actionable short with defined entry, stop and target sized for …

First Solar: Buy the Dip in a U.S. Solar Monopoly at a Reasonable Price

First Solar: Buy the Dip in a U.S. Solar Monopoly at a Reasonable Price

First Solar (FSLR) is a rare large-cap solar manufacturer that remains profitable, cash-flow positive, and undervalued versus its history and cash-generation profile. After a pullback tied to conservative 2026 guidance and political uncertainty over tax credits, the stock looks buyable at current levels: cheap on P/E, reasonable EV/EBITDA, strong b…

Myriad Genetics: Sum‑of‑the‑Parts Re‑Rate Could Double the Stock If MRD Commercialization Gains Traction

Myriad Genetics: Sum‑of‑the‑Parts Re‑Rate Could Double the Stock If MRD Commercialization Gains Traction

Myriad trades at a sub-0.5x price-to-sales multiple and an enterprise value of roughly $378M. A modest re‑rating toward 1.0x–1.5x P/S driven by MRD commercialization and reimbursement wins would imply meaningful upside from today's $4.50 share price. This trade idea buys the optionality with a defined stop and a clear multi-month horizon.

Buy SCHG into Strength: Large-Cap Growth at a Reasonable Entry

Buy SCHG into Strength: Large-Cap Growth at a Reasonable Entry

SCHG (Schwab U.S. Large-Cap Growth ETF) offers concentrated exposure to high-quality U.S. growth names at a valuation that still leaves room for upside. With a $48.3B market cap, a 10-year track record of outperformance, and a current price sitting below key moving averages, this trade idea targets a recovery to near-term highs while limiting downs…

Griffon Pullback: A Practical Mid‑Swing Long After the Rally

Griffon Pullback: A Practical Mid‑Swing Long After the Rally

Griffon (GFF) has ripped higher this year but still shows sensible fundamentals: free cash flow of $276.9M, ROE around 41%, low debt-to-equity and an EV/EBITDA of ~9.1. With momentum cooling and the stock 25% off its 52-week high, a disciplined mid-swing long at $72.00 with a stop at $66.00 and a target of $85.00 offers a favorable risk/reward for …

Northrim (NRIM): Cheap Regional Bank with a Clear Path to $30

Northrim (NRIM): Cheap Regional Bank with a Clear Path to $30

Northrim BanCorp (NRIM) trades at roughly $22.90 today, an attractive valuation (PE ~7.9, P/B ~1.54, EV/EBITDA ~6.5) for a profitable, well-capitalized regional bank. With consistent dividends, strong ROE (19.8%), and free cash flow of $133.9M versus a market cap near $507M, NRIM looks buyable for a long-term trade to $30 while limiting downside wi…

Nomad Foods: Position to Short as Macro Pressure Deepens

Nomad Foods: Position to Short as Macro Pressure Deepens

Nomad Foods looks cheap on paper — $1.36B market cap, P/E ~9.5 and a near 7% dividend yield — but an earnings hit from supply-chain inflation, sliding sales and an increasingly defensive consumer set the stage for further downside. This is a tactical short with a defined entry, stop and target over a mid-term (45 trading days) window.

MongoDB: Buy the Post-Guidance Dip — Atlas Re-acceleration Is Probable

MongoDB: Buy the Post-Guidance Dip — Atlas Re-acceleration Is Probable

MongoDB fell earlier this month after management set FY growth around 17%, but the selloff priced in a far worse outcome than the numbers support. Atlas remains the company’s durable growth engine, free cash flow is positive at roughly $500M last fiscal year, and valuation (market cap ~$19.6B) looks stretched but defendable if growth re-accelerates…

JLL: Buy the Recovery Narrative While Valuation Still Makes Sense

JLL: Buy the Recovery Narrative While Valuation Still Makes Sense

Jones Lang LaSalle (JLL) looks buyable here: the share price sits well below the 52-week high but valuation metrics - P/E ~18, EV/EBITDA ~9.7 and price-to-sales ~0.53 - leave room for upside if transaction volumes and asset values continue to recover. I lay out an actionable long trade with entry, stop and target calibrated to a 180-trading-day hor…

Bitdeer: A Crypto Miner Re-tooling to Capture AI Data Center Demand

Bitdeer: A Crypto Miner Re-tooling to Capture AI Data Center Demand

Bitdeer (BTDR) is a $2.03B market-cap operator of proprietary mining datacenters that now offers a credible pathway to repurpose capacity and engineering capability toward AI workloads. At $8.44, the stock factors in near-term execution risk from lawsuits and chip delays, but the combination of lower share price, below-peak valuation and recent tec…